April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Annexin II and its Role in Actin Cytoskeletal Organization in Trabecular Meshwork
Author Affiliations & Notes
  • P. Malone
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina
  • T. Inoue
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina
  • E. Calloway
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina
  • P. V. Rao
    Ophthalmology, Duke University School of Medicine, Durham, North Carolina
  • Footnotes
    Commercial Relationships  P. Malone, None; T. Inoue, None; E. Calloway, None; P.V. Rao, None.
  • Footnotes
    Support  NIH Grant EY018590
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 4871. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P. Malone, T. Inoue, E. Calloway, P. V. Rao; Annexin II and its Role in Actin Cytoskeletal Organization in Trabecular Meshwork. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4871.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Recently we identified Annexin II, a calcium-, phospholipid- and actin-binding molecule as one of the major cytoskeletal proteins in the trabecular meshwork ( TM ) tissue and cells. Here we explored the role of annexin II in actin-based cytoskeletal reorganization in the context of aqueous humor outflow through the TM.

Methods: : TM cells were isolated from human eyes and cultured to confluence. We studied the regulation of annexin II activity using physiological and pharmacological agents known to modulate annexin II expression and activity in other cell types, including dexamethasone, withaferin A and insulin. Serum starved confluent cultures of TM cells were treated with different concentrations of dexamethasone, withaferin A and insulin for 2 to 24 hrs. Cell lysates derived from these treatments were assessed for changes in protein levels of annexin II, tyrosine phosphorylated proteins and phosphorylated cofilin by immunoblot analysis. Confluent cultures of cells seeded on glass coverslips were also treated as described above in preparation for immunocytochemistry-based analysis of changes in actin cytoskeletal organization and tyrosine phosphorylated proteins.

Results: : Annexin II was found to be distributed equally to the cytosol and membrane fraction of TM cells. Both dexamethasone and withaferin A increased total annexin II protein, tyrosine phosphorylation of annexin II and cofilin phosphorylation in a dose dependent manner. Dexamethasone increases actin stress fibers and cross-linked actin networks (CLANs) in TM cells in a dose-dependent manner as evidenced by immunocytochemical analyses. Treatment with withaferin A and insulin, on the other hand, decreases actin stress fibers in association with increased tyrosine phosphorylation compared to controls.

Conclusions: : The data derived from these studies demonstrate that dexamethasone, a known intraocular pressure (IOP) increasing agent, induces increases in annexin II protein levels in TM cells in association with increased CLANs formation. Withaferin A, a commonly used plant component of Ayurvedic medicine and a known annexin II binding agent, induces actin depolymerization in TM cells. Further, insulin, which is known to activate annexin II activity via tyrosine phosphorylation, increases actin depolymerization and tyrosine phosphorylation in TM cells. These studies collectively reveal annexin II as a potential molecular target for the novel treatment of glaucoma and IOP.

Keywords: outflow: trabecular meshwork • cytoskeleton • signal transduction: pharmacology/physiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×